Valuation : Satellos Bioscience Inc.

Market Cap 202M 174M 165M 149M 280M 19.29B 281M 1.96B 752M 9.81B 758M 742M 31B P/E 2026 *
-4.48x
P/E 2027 * -5.99x
Enterprise Value 100M 86.4M 81.81M 74.15M 139M 9.58B 140M 972M 374M 4.87B 377M 368M 15.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day-5.24%
1 week+6.02%
Current month+1.46%
1 month-4.42%
3 months+64.59%
6 months+14.29%
Current year+66.67%
1 week 12.44
Extreme 12.44
14.34
1 month 12.11
Extreme 12.11
14.5
Current year 7.67
Extreme 7.67
18.98
1 year 7.32
Extreme 7.320002
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
20.28
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/8/26 Option

Director

10,608 0.0509%
18/8/26 Option

Director

10,608 0.0509%
18/8/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
-5.24%+6.02%+64.18%+115.69% 202M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.79%-2.05%+34.00%+234.29% 27.06B
Weighted average by Cap. -0.56%-2.82%+31.28%+170.61%

Financials

2026 *2027 *
Net sales - -
Net income -49.06M -42.27M -40.03M -36.28M -68.06M -4.69B -68.41M -475M -183M -2.38B -184M -180M -7.54B -62.88M -54.18M -51.3M -46.5M -87.23M -6.01B -87.67M -609M -234M -3.06B -236M -231M -9.66B
Net Debt -102M -87.54M -82.89M -75.13M -141M -9.71B -142M -984M -379M -4.94B -382M -373M -15.6B -119M -103M -97.08M -88M -165M -11.37B -166M -1.15B -443M -5.78B -447M -437M -18.28B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
11/09/26 CAD 13.20 -5.24% 7,102
10/09/26 CAD 13.93 +0.58% 10,503
09/09/26 CAD 13.85 +8.46% 22,450
08/09/26 CAD 12.77 +2.57% 31,108
04/09/26 CAD 12.45 -0.64% 1,103
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.20CAD
Average target price
17.67CAD
Spread / Average Target
+33.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!